Artelo Biosciences, Inc. (ARTL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 21, 2025

$1.18

P/E Ratio

N/A

Market Cap

$3.81M

Jan 25, 2024Feb 29, 2024Apr 3, 2024May 6, 2024Jun 10, 2024Jul 16, 2024Aug 19, 2024Sep 24, 2024Oct 29, 2024Dec 3, 2024Jan 21, 2025$10.00$20.00
  • SEMR
Description

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Metrics

Overview

  • HQSolana Beach, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerARTL
  • Price$1.18+2.61%

Trading Information

  • Market cap$3.81M
  • Float99.17%
  • Average Daily Volume (1m)27,069
  • Average Daily Volume (3m)33,623
  • EPS-$2.84

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$1.13M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$1.19M
  • EV-$1.13M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.60
Documents